Certuity LLC Sells 480 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Certuity LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,302 shares of the pharmaceutical company’s stock after selling 480 shares during the quarter. Certuity LLC’s holdings in Vertex Pharmaceuticals were worth $1,330,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of VRTX. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Vertex Pharmaceuticals by 19.0% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,096 shares of the pharmaceutical company’s stock worth $510,000 after buying an additional 175 shares in the last quarter. Empirical Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter worth about $879,000. Grove Bank & Trust increased its holdings in Vertex Pharmaceuticals by 5.7% in the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after buying an additional 22 shares in the last quarter. Creative Planning increased its holdings in Vertex Pharmaceuticals by 1.7% in the 3rd quarter. Creative Planning now owns 80,467 shares of the pharmaceutical company’s stock worth $37,424,000 after buying an additional 1,350 shares in the last quarter. Finally, Occidental Asset Management LLC increased its holdings in Vertex Pharmaceuticals by 51.7% in the 3rd quarter. Occidental Asset Management LLC now owns 695 shares of the pharmaceutical company’s stock worth $323,000 after buying an additional 237 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $455.22 on Wednesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The stock’s 50-day simple moving average is $435.95 and its 200-day simple moving average is $462.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of recent research reports. StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday. UBS Group lifted their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Stifel Nicolaus boosted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. Finally, Truist Financial boosted their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a report on Tuesday. Ten equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $505.29.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.